otrivin-allergy

24 HR
ALLERGY Relief Nasal Spray

Provides relief from allergy symptoms: sneezing, itchy and runny nose, itchy and watery eyes,nasal congestion and associated sinus discomfort.

60 metered dose

Buy Now

Only available UAE and Oman

120 metered dose

Buy Now

Only available in Gulf and Near East

By clicking the link above, you will be taken to an external website that is independently operated and not managed by GSK. GSK assumes no responsibility for the content on the website. If you do not wish to leave this website, do not click on the link above.

24 Hour Allergy Relief Nasal Spray

Prophylaxis and treatment of allergic rhinitis including hay fever and that caused by other airborne allergens such as house dust mite and animal dander.

 

  • Product claim

    Provides symptomatic relief of all major symptoms of allergies, such as: 

    · Runny nose
    · Sneezing
    · Itchy nose
    · Nasal congestion
    · Itchy and watery eyes

  • How it works

    How it works

    Your allergies can lead to fatigue, sleep disturbances, learning and attention problems, and impaired function at work and/or school.

    Symptoms of allergies are the result of an inflammatory process that involves much more than just histamine.

    Otri Allergy counteracts this inflammatory process to relieve all nasal symptoms.

    The active ingredient in Otri Allergy is an intranasal corticosteroid, a class considered by experts to be one of the most effective types of medication for treating moderate to severe allergy symptoms.

    Otri Allergy relieves allergy symptoms so you can actively participate in daily life

  • How to use

    How to use

    Adults aged 18 years and over:

    Recommended Dose for the prophylaxis and treatment of allergic rhinitis:

    . Two sprays into each nostril once a day, preferably in the morning.

    . In some cases two sprays into each nostril twice daily may be required.

    . The Maximum daily dose should not exceed four sprays into each nostril.

    . Once control is achieved, the dose should be titrated down to one spray in each nostril once a day.

    . The minimum dose at which effective control of symptoms is maintained should be used.

    . Prophylaxis of allergic rhinitis requires treatment before contact with allergen.

    . For full therapeutic benefit regular usage is recommended.

    . Maximum benefit may require 3-4 days of continuous treatment in some people.

    Elderly:

    . The normal adult dose should be used.

    Children under 18 years of age:

    . Should not be used by children and adolescents under "18 years of age"

    . For administration by the intranasal route (nose) only.

    . Shake gently before use.

    . Do not exceed the recommended dose.

    . Before use the bottle needs to be primed by pumping until a fine spray is produced.

    . For Full product information please refer to the pack. Always read the label prior to use.

    How to take Otri-Allergy Aqueous Nasal Spray?

    instructions
  • Product information

    Product information

    When to use

    Prophylaxis and treatment of allergic rhinitis including hay fever and that caused by other airborne allergens such as house dust mite and animal dander.

    This medicine also provides symptomatic relief of sneezing, itchy and runny nose, itchy and watery eyes, nasal congestion and associated sinus discomfort.

    Ingredients: Each spray contains: 50 micrograms of Fluticasone Propionate (0.05% w/w)

    Other ingredients: Dextrose (anhydrous), Microcrystalline cellulose & Sodium carboxymethylcellulose, Phenylethyl alcohol, Benzalkonium chloride, Polysorbate 80, Dilute hydrochloric acid and Purified water.

    Warnings & Precautions

    Before you take Otri-Allergy Aqueous Nasal spray:

    a. Do not take Otri-Allergy Aqueous Nasal Spray in case of: Hypersensitivity to Fluticasone propionate or any other ingredients in this product.

    b. Take special care with Otri-Allergy Aqueous Nasal Spray:

    Treatment should be stopped, or the advice of a doctor sought if an improvement is not seen within 7 days.

    This medicine should not be used for more than 3 months continuously without consulting a doctor..

    • Care must be taken when withdrawing patients from systemic steroid treatment, and commencing therapy, if there is any reason to suspect that their adrenal function is impaired.

    • Treatment with higher than recommended doses of nasal corticosteroids may result in clinically significant adrenal suppression.

    • Significant interactions between Fluticasone Propionate and potent inhibitors of the cytochrome P450 3A4 system e.g : Ketoconazole and protease inhibitors such as ritonavir and cobicistat, may occur.

    This may result in increased systemic exposure to Fluticasone Propionate.

    • Systemic effects of nasal corticosteroids have been reported particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Potential systemic effect may include Cushing’s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (Particularly in children).

    Warning about excipients:

    This product contains Benzalkonium Chloride which may cause bronchospasm

    c. Taking other medicines:

    Low plasma concentrations of fluticasone propionate are achieved after intranasal dosing, due to extensive first pass metabolism and high systemic clearance mediated by cytochrome P450 3A4. Hence, significant drug interactions are unlikely.

    • Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects.

    • Other inhibitors of cytochrome P450 3A4 produce negligible (erythromycin) and minor (ketoconazole) increases in systemic exposure to fluticasone propionate without notable reductions in serum cortisol concentrations. Care is advised when co-administering potent inhibitors (e.g. ketoconazole).

    • Ritonavir (a highly potent cytochrome P450 3A4 inhibitor) increased the fluticasone propionate plasma concentrations several hundred-fold, resulting in reduced serum cortisol concentrations. Cases of Cushing’s syndrome and adrenal suppression have been reported. The combination should be avoided unless the benefit outweighs the increased risk of systemic glucocorticoid side-effects.

    d. Pregnancy and Breast feeding:

    Medical opinion should be sought, before using this medicine, in the case of pregnancy or breast feeding.

    • As with other drugs, the use of intranasal fluticasone propionate during pregnancy and lactation requires that the benefits be weighed against possible risks associated with the product or with any alternative therap

    e. Driving and using machines:

    Unlikely to produce an effect.